Combined treatment of the BCL6 peptide inhibitor reteroinverso-BCL6 peptide inhibitor (RI-BPI) with imatinib prevented TKI resistance and potentiated the effects of imatinib observed in Ph+ ALL (Cerchietti et al., 2009; Duy et al., 2011). This evidence concerns the gene BCL6 and acute lymphoblastic leukemia.